局限性前列腺癌长期幸存者的治疗决策后悔:前列腺癌结局研究结果
研究评估了1994年10月至1995年10月在六个SEER肿瘤登记处之一诊断为局限性前列腺癌且年龄≤75岁的男性,完成15年随访调查者共934人,其中14.6%表达治疗决策后悔。多因素分析显示中度或重度性功能困扰、肠道功能困扰及PSA担忧与后悔正相关,诊断时年龄增加和知情决策与后悔负相关。
要点
- 934名长期幸存者中14.6%表达治疗决策后悔。
- 中度或重度性功能困扰者后悔风险升高(OR 2.77)。
- 知情决策与较低后悔相关,作者建议更好地告知治疗选择。
核心结论
- 后悔在局限性前列腺癌长期幸存者中相对不常报告,但更好地告知男性治疗选择、特别是保守治疗,可能有助于减轻长期后悔。
研究设计与样本
- 评估1994年10月至1995年10月在六个SEER肿瘤登记处之一诊断为局限性前列腺癌且诊断时年龄≤75岁的男性,完成15年随访调查。
主要发现
- 共调查934名参与者,占已知幸存者的69.3%。
- 队列中59.1%具有低风险肿瘤特征(PSA<10 ng/mL且Gleason评分<7),89.2%接受了积极治疗。
- 总体14.6%表达治疗决策后悔:保守治疗者8.2%,手术者15.0%,放疗者16.6%。
- 多因素分析中与后悔相关的因素包括中度或重度性功能困扰(报告率39.0%;OR 2.77;95%CI 1.51至5.0)、中度或重度肠道功能困扰(报告率7.7%;OR 2.32;95%CI 1.04至5.15)和PSA担忧(平均评分52.8;每点变化OR 1.01;95%CI 1.00至1.02)。
- 诊断时年龄增加和报告已做出知情治疗决策与后悔呈负相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To determine the demographic, clinical, decision-making, and quality-of-life factors that are associated with treatment decision regret among long-term survivors of localized prostate cancer. Patients and Methods We evaluated men who were age ≤ 75 years when diagnosed with localized prostate cancer between October 1994 and October 1995 in one of six SEER tumor registries and who completed a 15-year follow-up survey. The survey obtained demographic, socioeconomic, and clinical data and measured treatment decision regret, informed decision making, general- and disease-specific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on life. We used multivariable logistic regression analyses to identify factors associated with regret. Results We surveyed 934 participants, 69.3% of known survivors. Among the cohort, 59.1% had low-risk tumor characteristics (PSA < 10 ng/mL and Gleason score < 7), and 89.2% underwent active treatment. Overall, 14.6% expressed treatment decision regret: 8.2% of those whose disease was managed conservatively, 15.0% of those who received surgery, and 16.6% of those who underwent radiotherapy. Factors associated with regret on multivariable analysis included reporting moderate or big sexual function bother (reported by 39.0%; OR, 2.77; 95% CI, 1.51 to 5.0), moderate or big bowel function bother (reported by 7.7%; OR, 2.32; 95% CI, 1.04 to 5.15), and PSA concern (mean score 52.8; OR, 1.01 per point change; 95% CI, 1.00 to 1.02). Increasing age at diagnosis and report of having made an informed treatment decision were inversely associated with regret. Conclusion Regret was a relatively infrequently reported outcome among long-term survivors of localized prostate cancer; however, our results suggest that better informing men about treatment options, in particular, conservative treatment, might help mitigate long-term regret. These findings are timely for men with low-risk cancers who are being encouraged to consider active surveillance.
引用
- Hoffman RM, Lo M, Clark JA, et al. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. J Clin Oncol. 2017. PMID: 28493812. doi:10.1200/JCO.2016.70.6317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。